Quality of life outcomes among patients with depression after 6 months of starting treatment: Results from FINDER
Catherine Reed(Eli Lilly (United States)), Ángel L. Montejo(Universidad de Salamanca), Deborah Quail(Eli Lilly (United Kingdom)), Koen Demyttenaere(University Psychiatric Hospital), David Pérahia(École Normale Supérieure Paris-Saclay), Luigi Grassi(University of Ferrara), A Garcia-Cebrian(Eli Lilly (United Kingdom)), N. Dantchev, Michael Bauer, André Tylee(King's College London), Paul Gandhi(Eli Lilly (United Kingdom)), Brigitta U. Monz(Boehringer Ingelheim (Germany))
Cited by 67
Related Papers
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
|World Psychiatry|2023|751
Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys
|Epidemiology and Psychiatric Sciences|2015|626
The expanding role of primary care in cancer control
|The Lancet Oncology|2015|544
The associations between non-suicidal self-injury and first onset suicidal thoughts and behaviors
|Journal of Affective Disorders|2018|436
The identification, assessment and management of difficult-to-treat depression: An international consensus statement
|Journal of Affective Disorders|2020|277